Brooks Laboratories Limited (BOM:533543)
India · Delayed Price · Currency is INR 61.88
+2.48 (4.18%)
At close: Aug 21, 2026
Brooks Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 831.87 | 857.38 | 825.57 | 794.86 | 632.05 | 911.85 | |
Revenue Growth | -7.71% | 3.85% | 3.86% | 25.76% | -30.69% | 18.04% |
Cost of Revenue | 487.18 | 519.28 | 546.21 | 569.73 | 524.09 | 639.79 |
Gross Profit | 344.7 | 338.1 | 279.36 | 225.13 | 107.95 | 272.06 |
Selling, General & Admin | 161.5 | 156.05 | 132.73 | 107.94 | 176.94 | 194.68 |
Other Operating Expenses | 119.68 | 105.88 | 93.82 | 78.14 | 194.77 | 217.67 |
Operating Expenses | 297.31 | 277.84 | 242.56 | 203.82 | 441.97 | 485.86 |
Operating Income | 47.39 | 60.26 | 36.81 | 21.32 | -334.02 | -213.8 |
Interest Expense | -6.23 | -7.19 | -8.5 | -7.25 | -19.54 | -28.31 |
Interest & Investment Income | 1.88 | 1.88 | 2.95 | 1.07 | 1.27 | 0.91 |
Earnings From Equity Investments | 86.39 | 187.79 | -129.84 | -211.21 | -33.1 | - |
Currency Exchange Gain (Loss) | 1.38 | 1.38 | 1.4 | 1.53 | -0.43 | 2.22 |
Other Non Operating Income (Expenses) | -1.57 | -1.17 | -1.78 | -1.2 | -1.53 | -1.31 |
EBT Excluding Unusual Items | 129.24 | 242.95 | -98.97 | -195.74 | -387.35 | -240.29 |
Gain (Loss) on Sale of Investments | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | - |
Gain (Loss) on Sale of Assets | 2.8 | 2.8 | 0.1 | - | - | 1.31 |
Other Unusual Items | - | - | 0.88 | - | 3.57 | - |
Pretax Income | 132.12 | 245.84 | -97.92 | -195.66 | -383.7 | -238.98 |
Income Tax Expense | - | - | 1.75 | 0.26 | -73.24 | -45.85 |
Earnings From Continuing Operations | 132.12 | 245.84 | -99.67 | -195.92 | -310.46 | -193.13 |
Minority Interest in Earnings | - | - | - | - | 101.54 | 80.23 |
Net Income | 132.12 | 245.84 | -99.67 | -195.92 | -208.92 | -112.9 |
Net Income to Common | 132.12 | 245.84 | -99.67 | -195.92 | -208.92 | -112.9 |
Net Income Growth | 550.44% | - | - | - | - | - |
Shares Outstanding (Basic) | 29 | 29 | 27 | 26 | 25 | 25 |
Shares Outstanding (Diluted) | 29 | 29 | 27 | 26 | 25 | 25 |
Shares Change | 5.98% | 9.95% | 4.59% | 3.70% | - | - |
EPS (Basic) | 4.49 | 8.35 | -3.72 | -7.65 | -8.46 | -4.57 |
EPS (Diluted) | 4.49 | 8.35 | -3.72 | -7.65 | -8.46 | -4.57 |
EPS Growth | 513.72% | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 57.88 | 17.04 | -102.4 | -149.58 | -650.53 |
Free Cash Flow Per Share | - | 1.97 | 0.64 | -4.00 | -6.05 | -26.33 |
Gross Margin | 41.44% | 39.43% | 33.84% | 28.32% | 17.08% | 29.84% |
Operating Margin | 5.70% | 7.03% | 4.46% | 2.68% | -52.85% | -23.45% |
Profit Margin | 15.88% | 28.67% | -12.07% | -24.65% | -33.05% | -12.38% |
Free Cash Flow Margin | - | 6.75% | 2.06% | -12.88% | -23.67% | -71.34% |
EBITDA | 59.71 | 72.65 | 49.45 | 36.15 | -267.44 | -143.15 |
EBITDA Margin | 7.18% | 8.47% | 5.99% | 4.55% | -42.31% | -15.70% |
D&A For EBITDA | 12.32 | 12.39 | 12.65 | 14.83 | 66.58 | 70.65 |
EBIT | 47.39 | 60.26 | 36.81 | 21.32 | -334.02 | -213.8 |
EBIT Margin | 5.70% | 7.03% | 4.46% | 2.68% | -52.85% | -23.45% |
Revenue as Reported | 843.18 | 869.09 | 834.4 | 804.04 | 634.16 | 919.86 |
Advertising Expenses | - | 4.39 | 2.97 | 2.45 | 3.43 | 2.6 |